GYRE THERAPEUTICS, INC. (GYRE)
2025-06-30 | 2024-09-30 | |||
|---|---|---|---|---|
| Net income | 1,576 | 2,856 | ||
| Other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax, portion attributable to parent, total | 303 | - | ||
| Comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest | 1,879 | - | ||
| Other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax, portion attributable to noncontrolling interest | 104 | - | ||
| Net income (loss) attributable to noncontrolling interest, total | 1,134 | 1,732 | ||
| Comprehensive income (loss), net of tax, attributable to noncontrolling interest | 1,238 | - | ||
| Comprehensive income (loss), net of tax, attributable to parent | 641 | 1,124 | ||
| Net income attributable to common stockholders | - | 1,124 | ||
| Earnings per share, basic | - | 0.01 | ||
| Earnings per share, diluted | - | 0.01 | ||
| Weighted average number of shares outstanding, diluted | 102,701,707 | 102,640,373 | ||
| Weighted-average number of shares used in computing net income (loss) per share available to common stockholders, basic | 89,119,344 | 85,643,646 | ||